Literature DB >> 10362128

Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma.

K Furuta1, S Misao, K Takahashi, T Tagaya, Y Fukuzawa, T Ishikawa, K Yoshioka, S Kakumu.   

Abstract

Alteration of transforming growth factor beta1 (TGF-beta1) type II receptor (RII) appears to cause unresponsiveness to TGF-beta1 in tumorigenic cells. Defect in the mononucleotide repeat sequence, i.e., poly A region of TGF-beta1RII gene has been reported to be related to replication error-positive cancer cells. We examined if there is any TGF-beta1RII mutation in a coding microsatellite in hepatocellular carcinoma (HCC). Genomic DNAs were extracted from formalin-fixed, paraffin-embedded liver tissues obtained at surgery or autopsy in 3 normal individuals and 96 patients with hepatitis C virus-induced chronic liver disease; 3 with chronic hepatitis, 20 with liver cirrhosis and 73 with HCC. The DNA was PCR-amplified at 2 segments of TGF-beta1RII: poly A region which includes the (A)10 microsatellite sequence, and poly GT region. PCR products were directly sequenced. DNA from normal and patients with chronic liver disease contained the 10 wild-type adenines but 3 cases with liver cirrhosis in whom there were only 9 adenines within poly A tract. This microdeletion of one A resulted in a frameshift and truncated a predicted length of amino acids. In HCC lesions, the same deletion was noted in 4 cases (25%) of well-differentiated type, 10 (40%) of moderately differentiated type, 18 (53%) of poorly differentiated type. None of the lesions had mutations within the GT region. Our findings indicate that one adenine deletion of poly A microsatellite tract within TGF-beta1RII is frequently detected in patients with HCC, and the mutation may cause the abrogation of the function of TGF-beta1RII gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362128     DOI: 10.1002/(sici)1097-0215(19990611)81:6<851::aid-ijc2>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Charge movement and transcription regulation of L-type calcium channel alpha(1S) in skeletal muscle cells.

Authors:  Zhenlin Zheng; Zhong-Min Wang; Osvaldo Delbono
Journal:  J Physiol       Date:  2002-04-15       Impact factor: 5.182

2.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

Review 3.  Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.

Authors:  Takashi Yamaguchi; Katsunori Yoshida; Miki Murata; Koichi Matsuzaki
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

4.  Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.

Authors:  A Franchi; O Gallo; I Sardi; M Santucci
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

5.  Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation.

Authors:  Wenjun Ju; Atsushi Ogawa; Joerg Heyer; Dirk Nierhof; Liping Yu; Raju Kucherlapati; David A Shafritz; Erwin P Böttinger
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

6.  Detection of a rare oligo(A) repeat tract mutation (8As-->7As) in the sequence encoding the La/SS-B autoantigen.

Authors:  Imre Semsei; Shannon Maier; Jennifer Workman-Azbill; László Urbán; Kathy Moser; Margit Zeher; Michael Bachmann; A Darise Farris
Journal:  Anal Biochem       Date:  2007-07-05       Impact factor: 3.365

7.  Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

Authors:  Maria Serova; Annemilaï Tijeras-Raballand; Célia Dos Santos; Miguel Albuquerque; Valerie Paradis; Cindy Neuzillet; Karim A Benhadji; Eric Raymond; Sandrine Faivre; Armand de Gramont
Journal:  Oncotarget       Date:  2015-08-28

Review 8.  Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.

Authors:  Cindy Neuzillet; Armand de Gramont; Annemilaï Tijeras-Raballand; Louis de Mestier; Jérome Cros; Sandrine Faivre; Eric Raymond
Journal:  Oncotarget       Date:  2014-01-15

Review 9.  Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis.

Authors:  Katsunori Yoshida; Koichi Matsuzaki; Miki Murata; Takashi Yamaguchi; Kanehiko Suwa; Kazuichi Okazaki
Journal:  Cancers (Basel)       Date:  2018-06-05       Impact factor: 6.639

10.  TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells.

Authors:  Xiaoxin Mu; Shu Lin; Junhua Yang; Chen Chen; Yun Chen; Maryanne C Herzig; Kenneth Washburn; Glenn A Halff; Christi A Walter; Beicheng Sun; Lu-Zhe Sun
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.